Join Growin Stock Community!

West pharmaceutical services, inc.WST.US Overview

US StockHealthcare
(No presentation for WST)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

WST AI Insights

WST Overall Performance

WST AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

WST Recent Performance

-1.48%

West pharmaceutical services, inc.

0.05%

Avg of Sector

-0.31%

S&P500

WST PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

WST Key Information

WST Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

WST Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Price of WST

WST FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

WST Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.85
PE Ratio (TTM)
37.46
Forward PE
34.89
PS Ratio (TTM)
5.96
PB Ratio
5.65
Price-to-FCF
38.59
METRIC
VALUE
vs. INDUSTRY
Gross Margin
35.91%
Net Margin
16.06%
Revenue Growth (YoY)
6.25%
Profit Growth (YoY)
10.57%
3-Year Revenue Growth
4.34%
3-Year Profit Growth
5.06%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.85
PE Ratio (TTM)
37.46
Forward PE
34.89
PS Ratio (TTM)
5.96
PB Ratio
5.65
Price-to-FCF
38.59
Gross Margin
35.91%
Net Margin
16.06%
Revenue Growth (YoY)
6.25%
Profit Growth (YoY)
10.57%
3-Year Revenue Growth
4.34%
3-Year Profit Growth
5.06%

  • When is WST's latest earnings report released?

    The most recent financial report for West pharmaceutical services, inc. (WST) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating WST's short-term business performance and financial health. For the latest updates on WST's earnings releases, visit this page regularly.

  • Where does WST fall in the P/E River chart?

    According to historical valuation range analysis, West pharmaceutical services, inc. (WST)'s current price-to-earnings (P/E) ratio is 35.48, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of WST?

    According to the latest financial report, West pharmaceutical services, inc. (WST) reported an Operating Profit of 156.6M with an Operating Margin of 19.45% this period, representing a decline of 1.88% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is WST's revenue growth?

    In the latest financial report, West pharmaceutical services, inc. (WST) announced revenue of 805M, with a Year-Over-Year growth rate of 7.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does WST have?

    As of the end of the reporting period, West pharmaceutical services, inc. (WST) had total debt of 321.1M, with a debt ratio of 0.08. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does WST have?

    At the end of the period, West pharmaceutical services, inc. (WST) held Total Cash and Cash Equivalents of 791.3M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does WST go with three margins increasing?

    In the latest report, West pharmaceutical services, inc. (WST) achieved the “three margins increasing” benchmark, with a gross margin of 37.8%%, operating margin of 19.45%%, and net margin of 16.4%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess WST's profit trajectory and future growth potential.

  • Is WST's EPS continuing to grow?

    According to the past four quarterly reports, West pharmaceutical services, inc. (WST)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.83. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of WST?

    West pharmaceutical services, inc. (WST)'s Free Cash Flow (FCF) for the period is 175M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 105.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of WST?

    The latest valuation data shows West pharmaceutical services, inc. (WST) has a Price-To-Earnings (PE) ratio of 35.48 and a Price/Earnings-To-Growth (PEG) ratio of -6.64. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.